Unlu, Serhan
Kim, Joseph W. http://orcid.org/0000-0003-2222-3531
Funding for this research was provided by:
National Cancer Institute (UM1 CA186689)
Article History
Accepted: 13 June 2022
First Online: 6 August 2022
Declarations
:
: Serhan Unlu declares that he has no conflict of interest.Joseph W. Kim (JWK) is the study chair of one of the two NCI sponsored trials of olaparib, one of which is discussed in this review (NCI 9984).JWK also has received consulting fees from the following companies: Voluntis, Sanofi, EMD Serono and Clovis Oncology.JWK also received research funding from the following companies: Immune Design, Hummingbird, ADCT Therapeutics, Exelexis, Regeneron, Genetech/Roche, Cosmo Technologies.